PD-1 Inhibitor Market Poised For A New Round Of Expansion: After GSK’s Jemperli Approval, US FDA Still Has Three Novel Candidates Under Review
Agenus’ recent submission of balstilimab joins novel checkpoint inhibitors from Incyte expecting FDA action this year; Junshi and Coherus’ ongoing rolling BLA for toripalimab is the first from the multiple PD-1/L1 inhibitor candidates developed in China that are vying to enter the US market.
You may also be interested in...
Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10 years.
Combining Merck & Co’s pembrolizumab with chemotherapy first-line improves survival and PFS in metastatic cervical cancer, reinforcing its position in a condition in the sights of a number of other companies, although usually in later lines of therapy.
GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.